Filings Don’t Lie: Learn Why Mcmorran Doreen Just Purchased Skinvisible Inc Stake?

Filings Don't Lie: Learn Why Mcmorran Doreen Just Purchased Skinvisible Inc Stake?

The New Mcmorran Doreen Holding in Skinvisible Inc

Mcmorran Doreen filed with the SEC SC 13D/A form for Skinvisible Inc. The form can be accessed here: 000166357716000365. As reported in Mcmorran Doreen’s form, the filler as of late owns 52.64% or 135,684,316 shares of the -company.

Skinvisible Inc stake is a new one for the and it was filed because of activity on June 30, 2012. We feel this shows Mcmorran Doreen’s positive view for the stock.

Business Profile

Skinvisible, Inc. is a pharmaceutical research and development company. The Company has developed a polymer delivery system, Invisicare, and formulated over 40 topical skin products. The Company’s Invisicare manages the delivery of active ingredients for topically applied skin care products. The Company develops topical prescription and over-the-counter products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world. The Company assists pharmaceutical clients in the early development of optimal formulation. The Company sells a broad spectrum sun protection factor (SPF) 30 sunscreen known as Skinbrella. Its portfolio of sunless tanning products includes sunless tanning lotions (light, medium and dark), pre-sun moisturizer and after-sun moisturizer, along with sunless tanning spray products for commercial use. It has also developed approximately three broad spectrum sunscreens, with SPF 15, 30 and 50.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

The stock closed at $0.0106 during the last session. It is down 6.00% since October 3, 2016 and is uptrending. It has outperformed by 3.48% the S&P500.

Skinvisible, Inc. is a pharmaceutical research and development company. The company has a market cap of $1.28 million. The Firm has developed a polymer delivery system, Invisicare, and formulated over 40 topical skin products. It currently has negative earnings. The Company’s Invisicare manages the delivery of active ingredients for topically applied skin care products.

More notable recent Skinvisible Inc (OTCMKTS:SKVI) news were published by: Streetinsider.com which released: “Form 4 SKINVISIBLE INC For: Dec 31 Filed by: HOWLETT TERRY” on October 26, 2016, also Marketwired.com with their article: “Skinvisible’s Subsidiary Kintari Announces Network Marketing Expert Dean …” published on October 29, 2014, Prweb.com published: “Skinvisible’s Revolutionizing Sunscreen Brand Skinbrella® Highlighted by …” on June 17, 2016. More interesting news about Skinvisible Inc (OTCMKTS:SKVI) were released by: Reviewjournal.com and their article: “Canadian Olympic team using sanitizing lotion made by Las Vegas company” published on August 11, 2016 as well as Businesswire.com‘s news article titled: “Research and Markets: Global Anti-Aging Product Market 2014-2018: Beiersdorf …” with publication date: May 09, 2014.

According to Zacks Investment Research, “SKINVISIBLE PHARMACEUTICALS Inc., a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent.”

SKVI Company Profile

Skinvisible, Inc., incorporated on March 5, 1998, is a pharmaceutical research and development company. The Firm focuses on the development, manufacture and sales of topical, transdermal and mucosal polymer delivery system technologies and formulations incorporating its formula/process for combining hydrophilic and hydrophobic polymer emulsions. The Company, through its subsidiary Skinvisible Pharmaceuticals Inc., has developed a polymer delivery system, Invisicare. It has formulated over 40 topical skin products. Invisicare manages the delivery of active ingredients for topically applied skin care products. The Firm develops topical prescription and over-the-counter products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world. The Firm assists pharmaceutical clients in the early development of optimal formulation, which they then take forward into clinical testing. The Company’s technologies and formulations have various industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for women’s health, pain management, and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment